FDA Approves mFLUSIVA, Moderna’s First mRNA-Based Flu Vaccine

Company: Moderna · Event Type: FDA Approval · Product: mFLUSIVA (mRNA-1010) · Indication: Prevention of Seasonal Influenza · Population: Adults Age 50 and Older · Approval Date: August 5, 2026 Summary The FDA approved Moderna’s mFLUSIVA (mRNA-1010), the first mRNA-based seasonal influenza vaccine authorized in…